Expanding an existing 2018 collaboration on ‘mRNA’ vaccines for infectious diseases, Sanofi (NASDAQ:SNY) is strengthening its pact with Translate Bio (NASDAQ:TBIO) to develop shots for COVID-19 and the flu.
Messenger RNA technology is an alternative
approach to conventional vaccines that tries to defeat a pathogen by
injecting ribonucleic acid into the body that then teaches cells to
identify and attack the virus.
The deal could be valued at as much as $2.3B for
Translate Bio, with total upfront payments of $425M and potential future
milestones and other payments of up to $1.9B.
https://seekingalpha.com/news/3585229-sanofi-translate-bio-expand-mrna-vaccine-collaboration
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.